INNOVA CAPTAB
|
INNOVA CAPTAB Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 16.49 | 14.16 | 531.54 | 286.86 | 232.23 |
CEPS(Rs) | 19.28 | 16.46 | 14.89 | 8.35 | 7.91 |
DPS(Rs) | - | - | - | - | - |
Book NAV/Share(Rs) | 145.20 | 57.61 | 1,738.38 | 1,206.84 | 919.62 |
Tax Rate(%) | 27.16 | 25.97 | 25.39 | 25.56 | 25.70 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 14.25 | 12.09 | 11.88 | 13.24 | 13.62 |
EBIT Margin(%) | 13.93 | 11.89 | 11.31 | 12.21 | 11.27 |
Pre Tax Margin(%) | 11.95 | 9.76 | 10.60 | 11.26 | 10.03 |
PAT Margin (%) | 8.71 | 7.23 | 7.91 | 8.38 | 7.46 |
Cash Profit Margin (%) | 10.18 | 8.41 | 8.84 | 9.74 | 10.15 |
Performance Ratios | |||||
ROA(%) | 9.08 | 9.99 | 12.58 | 10.48 | 11.57 |
ROE(%) | 17.04 | 28.02 | 36.19 | 27.04 | 28.92 |
ROCE(%) | 19.06 | 24.34 | 30.64 | 28.42 | 26.48 |
Asset Turnover(x) | 1.04 | 1.38 | 1.59 | 1.25 | 1.55 |
Sales/Fixed Asset(x) | 3.48 | 4.46 | 5.17 | 4.10 | 4.07 |
Working Capital/Sales(x) | 3.45 | 5.70 | 9.56 | 7.44 | 7.37 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.29 | 0.22 | 0.19 | 0.24 | 0.25 |
Receivable days | 93.25 | 92.78 | 79.30 | 99.91 | 86.65 |
Inventory Days | 44.01 | 47.70 | 49.63 | 69.58 | 50.85 |
Payable days | 106.52 | 100.16 | 88.60 | 122.96 | 108.78 |
Valuation Parameters | |||||
PER(x) | 27.18 | - | - | - | - |
PCE(x) | 23.25 | - | - | - | - |
Price/Book(x) | 3.09 | - | - | - | - |
Yield(%) | - | - | - | - | - |
EV/Net Sales(x) | 2.52 | 0.29 | 0.26 | 0.11 | 0.16 |
EV/Core EBITDA(x) | 16.29 | 2.15 | 2.10 | 0.81 | 1.16 |
EV/EBIT(x) | 18.01 | 2.36 | 2.27 | 0.90 | 1.43 |
EV/CE(x) | 2.54 | 0.52 | 0.34 | 0.11 | 0.24 |
M Cap / Sales | 2.37 | - | - | - | - |
Growth Ratio | |||||
Net Sales Growth(%) | 16.72 | 15.72 | 94.94 | 10.00 | 4.92 |
Core EBITDA Growth(%) | 35.90 | 24.21 | 77.06 | 6.94 | 27.37 |
EBIT Growth(%) | 35.09 | 22.28 | 81.81 | 19.25 | 38.95 |
PAT Growth(%) | 38.84 | 6.26 | 85.37 | 23.72 | 40.30 |
EPS Growth(%) | 16.46 | -97.34 | 85.30 | 23.53 | 39.89 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.29 | 0.85 | 0.95 | 0.31 | 0.48 |
Current Ratio(x) | 2.07 | 1.59 | 1.27 | 1.26 | 1.39 |
Quick Ratio(x) | 1.58 | 1.17 | 0.86 | 0.83 | 0.89 |
Interest Cover(x) | 7.04 | 5.60 | 16.09 | 12.80 | 9.11 |
Total Debt/Mcap(x) | 0.09 | - | - | - | - |
Compare Financial Ratios of peers of INNOVA CAPTAB
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INNOVA CAPTAB | ₹4,487.6 Cr | 14.2% | -17.2% | 45.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹386,569.0 Cr | 2.8% | -7.5% | 2.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹146,318.0 Cr | -0.2% | -9.9% | 60.4% | Stock Analytics | |
CIPLA | ₹118,110.0 Cr | 4.4% | -0.6% | -1% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹103,926.0 Cr | 4.8% | -2.9% | 15.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹93,471.5 Cr | NA | -9.4% | -10.2% | Stock Analytics |
INNOVA CAPTAB Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INNOVA CAPTAB | 14.2% |
-17.2% |
45.7% |
SENSEX | 1.4% |
-5.3% |
0.3% |
You may also like the below Video Courses